Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

For patients with early-stage non-small cell lung cancer (NSCLC) driven by EGFR, ALK, or RET mutations, immunotherapy is largely off the table — but targeted therapies are filling that gap. New data from the NeoADAURA and ADAURA trials show strong benefits with osimertinib before and after surgery, and experts are now refining how to sequence, combine, and monitor these treatments for the best outcomes.
For patients with resectable NSCLC harboring oncogenic drivers like EGFR, ALK, or RET, immunotherapy isn't a viable option — which makes targeted therapy the cornerstone of perioperative care. Experts are now focused on optimizing how and when to deploy these agents around surgery to maximize long-term survival.
The ADAURA trial's 8-year update showed that adjuvant osimertinib cut the risk of death by nearly half in EGFR-mutant stage II–IIIA NSCLC (HR, 0.53), with 8-year overall survival of 74% vs. 58% for placebo. In the neoadjuvant space, the NeoADAURA trial demonstrated that osimertinib — with or without chemotherapy — dramatically improved major pathological response rates (25–26%) compared to just 2% with chemotherapy alone. The ongoing TARGET trial is now exploring whether extending adjuvant osimertinib from 3 to 5 years could push outcomes even further.
Beyond EGFR, early data on neoadjuvant lorlatinib in ALK-positive stage III NSCLC and adjuvant selpercatinib in RET fusion-positive disease are expanding the targeted therapy playbook.
By the Numbers:
Why it matters: As perioperative immunotherapy reshapes resectable NSCLC broadly, patients with oncogene-driven tumors need a parallel — and equally rigorous — treatment strategy. These emerging targeted therapy data are building that roadmap, with real implications for how clinicians test, treat, and monitor this growing patient population.